Cogent Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2015
Net Income	-212.17	-192.41	-140.24	-72.27	-179.21	-31.83	Upgrade
Depreciation & Amortization	3.93	3.59	5.88	1.99	0.72	1.29	Upgrade
Share-Based Compensation	34.16	30.62	18.37	11.69	6.02	3.24	Upgrade
Other Operating Activities	7.44	4.58	-2.64	-0.17	32.22	-14.22	Upgrade
Operating Cash Flow	-166.64	-153.62	-118.64	-58.76	-35.85	-41.51	Upgrade
Capital Expenditures	-1.76	-2.8	-6.86	-1.72	0.32	0.17	Upgrade
Acquisitions	0	0	0	0	8.1	0	Upgrade
Change in Investments	-154.9	-95.03	-117.86	0	0	22.99	Upgrade
Investing Cash Flow	-156.66	-97.82	-124.72	-1.72	8.42	23.16	Upgrade
Share Issuance / Repurchase	376.32	162.57	162.3	38.04	132.78	0	Upgrade
Other Financing Activities	0.83	0.97	1.26	-0.06	99.42	0.11	Upgrade
Financing Cash Flow	377.15	163.54	163.56	37.98	232.2	0.11	Upgrade
Net Cash Flow	53.85	-87.91	-79.8	-22.51	204.77	-18.25	Upgrade
Free Cash Flow	-168.4	-156.42	-125.5	-60.48	-35.53	-41.34	Upgrade
Free Cash Flow Margin	-	-	-	-	-451.40%	-183.75%	Upgrade
Free Cash Flow Per Share	-1.78	-1.96	-2.14	-1.56	-3.21	-5.43	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).